Shares in genedrive PLC soared over 27% on Wednesday morning after the company announced a host of international orders for its antibiotic induced hearing loss test.
Orders have been received from France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands for the MT-RNR1 test, genedrive announced, following recent commercial distribution agreements.
Genedrive’s MT-RNR1 test can be used by clinicians to make a decision on antibiotic use within half an hour, according to the company, which focuses on how genetics impact medicines within different people.
“We look forward to the continued expansion of our international sales throughout 2024,” chief executive James Cheek said.
Shares jumped 27.5% to 10.2p.